2012
DOI: 10.1016/j.jep.2012.08.046
|View full text |Cite
|
Sign up to set email alerts
|

Effect of decursin on the pharmacokinetics of theophylline and its metabolites in rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 33 publications
0
6
0
Order By: Relevance
“…Enoxacin and fluvoxamine are strong inhibitors of CYP1A2, and their activities were previously reported in an in vivo drug-interaction, where enoxacin was an inhibitor of CYP1A2 and fluvoxamine was a substrate (Kunii et al, 2005). Decursin, used as a traditional Asian medicine for examining the pharmacokinetics of theophylline in rats, is a typical substrate of CYP1A2 enzyme (Chae et al, 2012). The CYP2C subfamily is one of 12 CYP subfamilies in humans, which consist of four isoforms, namely CYP2C8, CYP2C9, CYP2C18, and CYP2C19, which metabolize about 25% of clinical drugs and share >82% sequence homology (Totah and Rettie, 2005;Xiaoping et al, 2013).…”
Section: Resultsmentioning
confidence: 92%
“…Enoxacin and fluvoxamine are strong inhibitors of CYP1A2, and their activities were previously reported in an in vivo drug-interaction, where enoxacin was an inhibitor of CYP1A2 and fluvoxamine was a substrate (Kunii et al, 2005). Decursin, used as a traditional Asian medicine for examining the pharmacokinetics of theophylline in rats, is a typical substrate of CYP1A2 enzyme (Chae et al, 2012). The CYP2C subfamily is one of 12 CYP subfamilies in humans, which consist of four isoforms, namely CYP2C8, CYP2C9, CYP2C18, and CYP2C19, which metabolize about 25% of clinical drugs and share >82% sequence homology (Totah and Rettie, 2005;Xiaoping et al, 2013).…”
Section: Resultsmentioning
confidence: 92%
“…From days 15 to 25, the rats were challenged on 10 consecutive days with the administration of 1 mg/mL or 2% OVA inhalation, 30 min/day. The normal control group received the same volume of saline subcutaneously (days 8 and 15) and inhalation (days [15][16][17][18][19][20][21][22][23][24][25].…”
Section: Grouping and The Asthma Modelmentioning
confidence: 99%
“…NF-κB activation is also closely associated with airway tissue remodeling (fibrosis of surrounding airway tissues, hyperplasia and hypertrophy of smooth muscle cells, and myxogenesis) (14). When asthmatics have airway inflammation and hyperresponsiveness, NF-κB and its inflammatory factors can reduce the metabolic clearance activity of theophylline and increase the incidence of theophylline accumulation toxicity, which is more likely to occur in children and elderly patients (15,16). NF-κB, a key factor in the inflammatory process, regulates the gene expression of cytochrome P450 3A (CYP3A) through the pregnane X receptor (PXR), thereby affecting drug metabolism (17).…”
Section: Introductionmentioning
confidence: 99%
“…Three different Angelica species have been recorded to contain the most active principle, decursin 44 . Decursin, has various pharmacological properties, including anticancer, anti-bacterial, platelet aggregation inhibitor and anti-inflammatory effects 45 . A study has pointed out that decursin suppressed the activities of CYP1A2, CYP2D15, and CYP3A12 in canine liver microsomes 46 .…”
Section: Angelica Speciesmentioning
confidence: 99%
“…So, chronic use of decursin with TPH concomitantly could elevate the concentration of TPH in the blood. There are suggestions about the interaction of decursin with CYP1A2 substrates 45 .…”
Section: Angelica Speciesmentioning
confidence: 99%